Fanouriakis A, Tziolos N, Bertsias G et al (2021) Update in the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis 80:14–25. https://doi.org/10.1136/annrheumdis-2020-218272

Article  PubMed  Google Scholar 

Dörner T, Furie R (2019) Novel paradigms in systemic lupus erythematosus. Lancet 393:2344–2358. https://doi.org/10.1016/s0140-6736(19)30546-x

Article  PubMed  Google Scholar 

Fanouriakis A, Kostopoulou M, Andersen J et al (2024) EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 83:15–29. https://doi.org/10.1136/ard-2023-224762

Article  CAS  PubMed  Google Scholar 

Van Vollenhoven RF, Mosca M, Bertsias G et al (2014) Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 73:958–967. https://doi.org/10.1136/annrheumdis-2013-205139

Article  PubMed  Google Scholar 

Mok CC, Hamijoyo L, Kasitanon N et al (2021) The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosus. Lancet Rheumatol 3:e517-531. https://doi.org/10.1016/S2665-9913(21)00009-6

Article  CAS  PubMed  Google Scholar 

Gordon C, Amissah-Arthur MB, Gayed M et al (2018) The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology 57:E1–E45. https://doi.org/10.1093/rheumatology/kex286

Article  PubMed  Google Scholar 

Fanouriakis A, Kostopoulou M, Alunno A et al (2019) 2019 Update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 78:736–745. https://doi.org/10.1136/annrheumdis-2019-215089

Article  CAS  PubMed  Google Scholar 

Gladman DD, Urowitz MB, Keystone EC (1979) Serologically active clinically quiescent systemic lupus erythematosus: a discordance between clinical and serologic features. Am J Med 66:210–215. https://doi.org/10.1016/0002-9343(79)90529-1

Article  CAS  PubMed  Google Scholar 

Steiman AJ, Gladman DD, Ibañez D et al (2010) Prolonged serologically active clinically quiescent systemic lupus erythematosus: frequency and outcome. J Rheumatol 37:1822–1827. https://doi.org/10.3899/jrheum.100007

Article  PubMed  Google Scholar 

Floris A, Piga M, Cauli A et al (2016) Predictors of flares in systemic lupus erythematosus: preventive therapeutic intervention based on serial anti-dsDNA antibodies assessment. Analysis of a monocentric cohort and literature review. Autoimmun Rev 15:656–663. https://doi.org/10.1016/j.autrev.2016.02.019

Article  CAS  PubMed  Google Scholar 

Ji L, Xie W, Fasano S et al (2022) Risk factors of flare in patients with systemic lupus erythematosus after glucocorticoids withdrawal. A systematic review and meta-analysis. Lupus Sci Med. 9:e000603. https://doi.org/10.1136/lupus-2021-000603

Article  PubMed  PubMed Central  Google Scholar 

Tseng CE, Buyon JP, Kim M et al (2006) The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54:3623–3632. https://doi.org/10.1002/art.22198

Article  CAS  PubMed  Google Scholar 

Bootsma H, Spronk P, Derksen R et al (1995) Prevention of relapses in systemic lupus erythematosus. Lancet 345:1595–1599. https://doi.org/10.1016/S0140-6736(95)90114-0

Article  CAS  PubMed  Google Scholar 

van Vollenhoven RF, Bertsias G, Doria A et al (2021) 2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Sci Med 8:e000538. https://doi.org/10.1136/lupus-2021-000538

Article  PubMed  PubMed Central  Google Scholar 

Pineda L, Zhong ZJ, Freimuth W et al (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377:721–752. https://doi.org/10.1016/S0140-6736(10)61354-2

Article  CAS  PubMed  Google Scholar 

Furie R, Petri M, Zamani O et al (2011) A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63:3918–3930. https://doi.org/10.1002/art.30613

Article  CAS  PubMed  PubMed Central  Google Scholar 

Furie RA, Morand EF, Bruce IN et al (2019) Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol 1:e208–e219. https://doi.org/10.1016/S2665-9913(19)30076-1

Article  PubMed  Google Scholar 

Morand EF, Furie R, Tanaka Y et al (2020) Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 382:211–221. https://doi.org/10.1056/NEJMoa1912196

Article  CAS  PubMed  Google Scholar 

Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725. https://doi.org/10.1002/art.1780400928

Article  CAS  PubMed  Google Scholar 

Huang H, Mu L, Zhang Z et al (2021) Treatments and outcomes in Chinese patients with serologically active clinically quiescent systemic lupus erythematosus: a retrospective observational study. Arthritis Res Ther. 23:275. https://doi.org/10.1186/s13075-021-02641-5

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gladman DD, Ibañez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29:288–291

PubMed  Google Scholar 

Franklyn K, Lau CS, Navarra SV et al (2016) Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis 75:1615–1621. https://doi.org/10.1136/annrheumdis-2015-207726

Article  CAS  PubMed  Google Scholar 

Petri M, Buyon J, Kim M (1999) Classification and definition of major flares in SLE clinical trials. Lupus 8:685–691. https://doi.org/10.1191/096120399680411281

Article  CAS  PubMed  Google Scholar 

Iudici M, Porcher R, Riveros C et al (2019) Time-dependent biases in observational studies of comparative effectiveness research in rheumatology. A methodological review. Ann Rheum Dis 78:562–569. https://doi.org/10.1136/annrheumdis-2018-214544

Article  CAS  PubMed  Google Scholar 

Miyazaki Y, Nakayamada S, Sonomoto K et al (2022) Efficacy and safety of belimumab during maintenance therapy in patients with systemic lupus erythematosus. Rheumatology 61:3614–3426. https://doi.org/10.1093/rheumatology/keab953

Article  CAS  PubMed  Google Scholar 

Bell CF, Chung J, Rubin B (2023) Real-world clinical outcomes in belimumab-treated US African American and Hispanic patients with systemic lupus erythematosus: a retrospective, observational study. Rheumatol Ther 10:447–462. https://doi.org/10.1007/s40744-022-00524-y

Article  PubMed  PubMed Central  Google Scholar 

Hammam N, Evans M, Bell CF et al (2022) Evaluating the use of glucocorticoids among belimumab-treated patients with systemic lupus erythematosus in real-world settings using the Rheumatology Informatics System for Effectiveness Registry. ACR Open Rheumatol 4:883–889. https://doi.org/10.1002/acr2.11482

Article  PubMed  PubMed Central  Google Scholar 

Babini A, Cappuccio AM, Caprarulo C et al (2020) Evaluation of belimumab treatment in patients with systemic lupus erythematosus in a clinical practice setting: Results from a 24-month OBSErve study in Argentina. Lupus 29:1385–1396. https://doi.org/10.1177/0961203320947814

Article  CAS  PubMed  PubMed Central  Google Scholar